STI571: A paradigm of new agents for cancer therapeutics

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 325-334

  Mauro, Michael J ^a   O'Dwyer, Michael ^a   Heinrich, Michael C ^a   Druker, Brian J ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; EDEMA; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MUSCLE CRAMP; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RASH; THERAPY RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0036139993     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.325     Document Type: Article

References (65)

1. Chronic myeloid leukemia
2. Chronic myelogenous leukemia: Biology and therapy
3. Current status of treatment for chronic myelogenous leukemia
4. A minute chromosome in human chronic granulocytic leukemia
5. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining
6. The viral and cellular forms of the Abelson (abl) oncogene
7. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia
8. The molecular biology of chronic myeloid leukemia
9. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
10. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties
11. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
12. Protein-tyrosine kinases
13. An alteration of the human c-abl protein in K562 unmasks associated tyrosine kinase activity
14. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
15. Acute leukaemia in bcr/abl transgenic mice
16. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
17. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
18. Reversibility of acute B-cell leukaemia induced by BCR-ABL 1
19. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
20. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
21. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
22. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
23. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
24. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
25. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: Activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
26. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins
27. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
28. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
29. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
30. Clinical pharmacokinetics and pharmacodynamics of STI571 in a phase 1 trial in chronic myelogenous leukemia (CML) patients
31. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
32. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia
33. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
34. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
35. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group
36. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
37. Chronic myeloid leukemia: Current treatment options
38. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
39. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
40. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
41. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
42. Protein tyrosine kinases and cancer
43. Involvement of platelet-derived growth factor in disease: Development of specific antagonists
44. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
45. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
46. Biological and clinical review of stromal tumors in the gastrointestinal tract
47. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
48. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-KIT (CD117)
49. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
50. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor
51. STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis
52. The selective tyrosine kinase inhibitor STI 571 inhibits small cell lung cancer growth
53. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
54. Identification of molecular endpoints as a guide for clinical decision making in STI571-treated chronic myelogenous leukemia patients
55. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
56. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
57. Induction of resistance to the Abelson inhibitor STI 571 in human leukemic cells through gene amplification
58. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCRABL(+) leukemic cells to the abl inhibitor STI 571
59. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
60. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
61. Ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
62. Efficacy of an Abl tyrosine kinase inhibitor in conjunction with other anti-leukemic agents against Bcr-Abl positive cells
63. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
64. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
65. Diffuse large B cell lymphoma outcome prediction by gene expression profiling